GLPG1837: Phase IIa SAPHIRA 2 data

Data from 7 patients with S1251N mutation-positive CF in the open-label, international Phase IIa SAPHIRA 2 trial showed that twice-daily oral GLPG1837 was generally well tolerated with no serious adve...